Connect with us
Mason Capital, owning 2.1% of Grifols' Class A shares, seeks Tomás Dagá's resignation, citing governance concerns and shareholder value loss. The fund demands transparency on Dagá’s...
Spanish pharmaceutical stocks dropped 10% in November, led by Rovi's 17.5% plunge amid profit and turnover declines. Grifols also fell 16%, impacted by OPA cancellation and...
Gotham City raises doubts about Grifols following Brookfield's withdrawal from a takeover bid, claiming the firm lacked access to crucial data. Grifols shares dropped 14%, compounding...
Brookfield agreed with Santander and Deutsche Bank to raise €11 billion for Grifols' debt refinancing, potentially Spain's largest syndicated loan. This funding is vital for Brookfield’s...
Grifols achieved its best score in the S&P Global Sustainability ranking with 70 points, improving by seven from last year. The ranking recognized its advancements in...
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....
JPMorgan Chase reduced its stake in Grifols from 3.09% to 2.99% as Brookfield seeks sovereign fund partners for a potential takeover bid. JPMorgan's 12.7 million shares...
Grifols shares rose 2.6% following reports that Canadian firm Brookfield is in informal talks with sovereign funds for a takeover bid. Brookfield is seeking €9.5 billion...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...